TET2

Summary

Gene Symbol: TET2
Description: tet methylcytosine dioxygenase 2
Alias: KIAA1546, MDS, methylcytosine dioxygenase TET2, tet oncogene family member 2
Species: human
Products:     TET2

Top Publications

  1. Abdel Wahab O, Mullally A, Hedvat C, Garcia Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114:144-7 pubmed publisher
    ..Based on the recent identification of TET2 mutations, we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), ..
  2. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116:1132-5 pubmed publisher
    Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms...
  3. Mohamedali A, Smith A, Gaken J, Lea N, Mian S, Westwood N, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol. 2009;27:4002-6 pubmed publisher
    ..We investigated the sequence integrity of 4q24 candidate tumor suppressor gene TET2 in MDS patients with UPD on chromosome 4...
  4. Zhang Q, Liu X, Gao W, Li P, Hou J, Li J, et al. Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked ?-N-acetylglucosamine transferase (OGT). J Biol Chem. 2014;289:5986-96 pubmed publisher
    ..Although TET1 and TET2 also interact with and can be O-GlcNAcylated by OGT, neither their subcellular localization nor their enzymatic ..
  5. Asmar F, Punj V, Christensen J, Pedersen M, Pedersen A, Nielsen A, et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 2013;98:1912-20 pubmed publisher
    ..Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigations have shown TET2 mutations in diffuse ..
  6. Bejar R, Lord A, Stevenson K, Bar Natan M, Pérez Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705-12 pubmed publisher
    ..The overall response rate of 47% was not different between agents. Clonal TET2 mutations predicted response (odds ratio [OR] 1.99, P = ...
  7. Tefferi A, Lim K, Abdel Wahab O, Lasho T, Patel J, Patnaik M, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23:1343-5 pubmed publisher
  8. Jankowska A, Szpurka H, Tiu R, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113:6403-10 pubmed publisher
    ..We then investigated genes in the commonly affected area for mutations. When we sequenced TET2, we found homozygous and hemizygous mutations...
  9. Abdel Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18:117-23 pubmed publisher
    ..mutations in genes which appear to affect the epigenome of MPN patients have been discovered including mutations in TET2, IDH1/ 2, EZH2, and ASXL1...

More Information

Publications78

  1. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler K, Shen L, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7:201-7 pubmed publisher
    b>TET2 enzymatically converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine, possibly leading to loss of DNA methylation...
  2. Deplus R, Delatte B, Schwinn M, Defrance M, Méndez J, Murphy N, et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 2013;32:645-55 pubmed publisher
    ..has linked TET1 function to epigenetic repression complexes, yet mechanistic information, especially for the TET2 and TET3 proteins, remains limited...
  3. Saint Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114:1628-32 pubmed publisher
    ..A putative tumor suppressor gene, TET2, was recently implicated in MPN and myelodysplastic syndromes through the identification of acquired mutations ..
  4. Kosmider O, Gelsi Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676-81 pubmed publisher
    Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 (Ten-Eleven Translocation-2) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including ..
  5. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128-38 pubmed publisher
    ..a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), Casitas B-lineage lymphoma proto-oncogene (CBL), ..
  6. Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen M, Slovak M, et al. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. Hum Mol Genet. 2010;19:1507-14 pubmed publisher
    ..partial uniparental disomies for 9p (one case) and 4q (two cases) associated with homozygous mutations of JAK2 and TET2, respectively...
  7. Szpurka H, Jankowska A, Makishima H, Bodo J, Bejanyan N, Hsi E, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010;34:969-73 pubmed publisher
    ..Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes...
  8. Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011;118:2551-5 pubmed publisher
    b>TET2 converts 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) in DNA and is frequently mutated in myeloid malignancies, including myeloproliferative neoplasms...
  9. Smith A, Mohamedali A, Kulasekararaj A, Lim Z, Gaken J, Lea N, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116:3923-32 pubmed publisher
    Mutations in the TET2 gene are frequent in myeloid disease, although their biologic and prognostic significance remains unclear...
  10. Figueroa M, Abdel Wahab O, Lu C, Ward P, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553-67 pubmed publisher
    ..In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the ?-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants...
  11. Tefferi A, Levine R, Lim K, Abdel Wahab O, Lasho T, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900-4 pubmed publisher
    TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms...
  12. Schaub F, Looser R, Li S, Hao Shen H, Lehmann T, Tichelli A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115:2003-7 pubmed publisher
    Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F...
  13. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica. 2010;95:518-9 pubmed publisher
  14. Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, et al. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell. 2013;155:1545-55 pubmed publisher
    ..Mutations of TET2 are frequently observed in myeloid malignance...
  15. Nguyen Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, et al. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer. 2010;49:919-27 pubmed publisher
    ..JAK2V617F and TET2 mutations were searched for in 40 and 32 patients, respectively. Significantly more -7/del(7q) (P = 0...
  16. Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858-65 pubmed publisher
    ..In addition, complete coding regions were analyzed for RUNX1 (beta isoform) and TET2 aberrations. Cytogenetic aberrations were found in 18.2% of patients (14 of 77 patients)...
  17. Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41:838-42 pubmed publisher
    ..sequencing in 102 individuals with MDS and identified acquired deletions and missense and nonsense mutations in the TET2 gene in 26% of these individuals...
  18. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-301 pubmed publisher
    ..The coding sequence of this gene, TET2, was determined in 320 patients...
  19. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of ?-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17-30 pubmed publisher
    ..Hence, tumor-derived IDH1 and IDH2 mutations reduce ?-KG and accumulate an ?-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations. ..
  20. Lorsbach R, Moore J, Mathew S, Raimondi S, Mukatira S, Downing J. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17:637-41 pubmed
  21. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26:934-42 pubmed publisher
    We investigated ten-eleven translocation 2 (TET2) mutations in acute myeloid leukemia (AML), their correlation with other gene mutations and prognostic value. By deep-sequencing, 131 somatic TET2 mutations were identified in 87/318 (27...
  22. Ko M, Huang Y, Jankowska A, Pape U, Tahiliani M, Bandukwala H, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839-43 pubmed publisher
    b>TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA...
  23. Langlois T, da Costa Reis Monte Mor B, Lenglet G, Droin N, Marty C, Le Couedic J, et al. TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. Stem Cells. 2014;32:2084-97 pubmed publisher
    Ten-eleven-translocation 2 (TET2) belongs to the TET protein family that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine and plays a central role in normal and malignant adult hematopoiesis...
  24. Kim Y, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M, et al. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol. 2011;64:850-2 pubmed publisher
    Miscoding mutations of the TET2 gene, which encodes the ?-ketoglutarate-dependent enzyme that catalyses the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, thus producing DNA demethylation, have been detected in 10-25% of acute ..
  25. Couronné L, Lippert E, Andrieux J, Kosmider O, Radford Weiss I, Penther D, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010;24:201-3 pubmed publisher
  26. Chen Q, Chen Y, Bian C, Fujiki R, Yu X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature. 2013;493:561-4 pubmed publisher
    Ten eleven translocation (TET) enzymes, including TET1, TET2 and TET3, convert 5-methylcytosine to 5-hydroxymethylcytosine and regulate gene transcription...
  27. Gelsi Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365-75 pubmed publisher
    ..and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1...
  28. Busque L, Patel J, Figueroa M, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179-81 pubmed publisher
    ..of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing...
  29. Tefferi A, Pardanani A, Lim K, Abdel Wahab O, Lasho T, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905-11 pubmed publisher
    High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA from 239 patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs)...
  30. Soucie E, Hanssens K, Mercher T, Georgin Lavialle S, Damaj G, Livideanu C, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012;120:4846-9 pubmed publisher
    ..number of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease...
  31. Traina F, Visconte V, Jankowska A, Makishima H, O Keefe C, Elson P, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE. 2012;7:e43090 pubmed publisher
    ..areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family...
  32. Moran Crusio K, Reavie L, Shih A, Abdel Wahab O, Ndiaye Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11-24 pubmed publisher
    Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies...
  33. Muramatsu H, Makishima H, Jankowska A, Cazzolli H, O Keefe C, Yoshida N, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood. 2010;115:1969-75 pubmed publisher
    ..In total, c-Cbl mutations were detected in 5 (10%) of 49 patients. No mutations were identified in Cbl-b and TET2. c-Cbl and RAS pathway mutations were mutually exclusive...
  34. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183-6 pubmed publisher
  35. Kosmider O, Gelsi Boyer V, Cheok M, Grabar S, Della Valle V, Picard F, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285-91 pubmed publisher
    ..of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS...
  36. Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25-38 pubmed publisher
    ..We report that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a ..
  37. Patel B, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017;31:2815-2823 pubmed publisher
    ..While most CMML patients (59%) had ancestral (dominant/co-dominant) mutations involving TET2, SRSF2 or ASXL1 genes, secondary subclonal hierarchy correlated with clinical phenotypes or outcomes...
  38. Itzykson R, Kosmider O, Cluzeau T, Mansat de Mas V, Dreyfus F, Beyne Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147-52 pubmed publisher
    The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported...
  39. Li J, Li W, Yin H, Zhang B, Zhu W. [Effect of cadmium on TET enzymes and DNA methylation changes in human embryonic kidney cell]. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49:822-7 pubmed
    ..23 ± 0.13, 0.48 ± 0.12, 0.59 ± 0.16 and 0.95 ± 0.39, respectively (F = 182.89, P = 0.002); The level of TET2 mRNA in groups of 0.0, 0.5, 1.0, 2.0 µmol/L were 0.23 ± 0.12, 0.32 ± 0.02,0.31 ± 0.10 and 0.34 ± 0...
  40. Zhang X, Su J, Jeong M, Ko M, Huang Y, Park H, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014-23 pubmed publisher
    Mutations in the epigenetic modifiers DNMT3A and TET2 non-randomly co-occur in lymphoma and leukemia despite their epistasis in the methylation-hydroxymethylation pathway...
  41. Chapman J, Geyer J, Khanlari M, Moul A, Casas C, Connor S, et al. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol. 2017;: pubmed publisher
    ..but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, ..
  42. Huang L, Liu D, Wang N, Ling S, Tang Y, Wu J, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2017;: pubmed publisher
    ..0001) in the plasma of all patients examined. Additional frequently mutated genes included TP53 (34%), TET2 (28%), CREBBP (21%) and MLL2 (21%)...
  43. Obeng E, Chappell R, Seiler M, Chen M, Campagna D, Schmidt P, et al. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016;30:404-417 pubmed publisher
    ..b>Tet2 loss cooperates with Sf3b1(K700E) to cause a more severe erythroid and LT-HSC phenotype...
  44. Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, et al. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice. Cancer Med. 2017;6:349-360 pubmed publisher
    ..Multivariate analysis showed that karyotypes and mutation status of TET2, PHF6, KIT, and NPM1mutation /FLT3- internal tandem duplication (ITD)negative were ..
  45. Kao H, Liang D, Kuo M, Wu J, Dunn P, Wang P, et al. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget. 2015;6:33217-25 pubmed publisher
    ..66% of patients had gene mutations involving epigenetic regulation, and DNMT3A (32.7%), IDH2 (18.4%), TET2 (18.4%), and IDH1 (10.2%) mutations were most common...
  46. Chen B, Lei Y, Wang H, Dang Y, Fang P, Wang J, et al. Repression of the expression of TET2 by ZEB1 contributes to invasion and growth in glioma cells. Mol Med Rep. 2017;15:2625-2632 pubmed publisher
    ..The suppressive role of ten-eleven translocation 2 (TET2) has been implicated in certain types of cancer, however, its role in gliomas remains to be elucidated...
  47. Guo S, Jiang X, Wang Y, Chen L, Li H, Li X, et al. The protective role of TET2 in erythroid iron homeostasis against oxidative stress and erythropoiesis. Cell Signal. 2017;38:106-115 pubmed publisher
    ..Interestingly, global 5hmC content and TET2 expression were significantly induced by oxidative stress, whereas antioxidant had the opposite's effect...
  48. Soulieres D, Licitra L, Mesia R, Remenar E, Li S, Karpenko A, et al. Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clin Cancer Res. 2018;24:2505-2516 pubmed publisher
    ..The most frequently (>5%) mutated genes were TP53, FAT1, TET2, KMT2D, PIK3CA, NOTCH1, NFE2L2, NOTCH2, CCND1, and CDKN2A Patients with SCCHN tumors (from various ..
  49. Foksinski M, Zarakowska E, Gackowski D, Skonieczna M, Gajda K, Hudy D, et al. Profiles of a broad spectrum of epigenetic DNA modifications in normal and malignant human cell lines: Proliferation rate is not the major factor responsible for the 5-hydroxymethyl-2'-deoxycytidine level in cultured cancerous cell lines. PLoS ONE. 2017;12:e0188856 pubmed publisher
    ..The expression levels of TET1, TET2, TET3, SMUG1, and TDG genes were also assayed by RT-qPCR...
  50. Mulholland C, Smets M, Schmidtmann E, Leidescher S, Markaki Y, Hofweber M, et al. A modular open platform for systematic functional studies under physiological conditions. Nucleic Acids Res. 2015;43:e112 pubmed publisher
    ..For the systematic study of epigenetic factors, including Dnmt1, Dnmt3a, Dnmt3b, Tet1, Tet2, Tet3 and Uhrf1, we generated MIN-tagged embryonic stem cell lines and created a toolbox of prefabricated modules ..
  51. Ko M, An J, Bandukwala H, Chavez L, Aijö T, Pastor W, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497:122-6 pubmed publisher
    ..of Wnt signalling that has been implicated in malignant renal cell carcinoma and colonic villous adenoma, regulates TET2 protein expression...
  52. Ustun C, Arock M, Kluin Nelemans H, Reiter A, Sperr W, George T, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101:1133-1143 pubmed
    ..These include TET2, SRSF2, ASXL1, RUNX1, JAK2, and/or RAS mutations, which may adversely impact prognosis and survival in particular ..
  53. Chim C, Wan T, Fung T, Wong K. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol. 2010;63:942-6 pubmed publisher
    A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm...
  54. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross N, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25:877-9 pubmed publisher
  55. Rakoczy J, Padmanabhan N, Krzak A, Kieckbusch J, Cindrova Davies T, Watson E. Dynamic expression of TET1, TET2, and TET3 dioxygenases in mouse and human placentas throughout gestation. Placenta. 2017;59:46-56 pubmed publisher
    ..Here, we determine the spatiotemporal expression of TET1, TET2, and TET3 in specific trophoblast cell populations of mouse and human placentas throughout gestation, and consider ..
  56. Guilhamon P, Eskandarpour M, Halai D, Wilson G, Feber A, Teschendorff A, et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun. 2013;4:2166 pubmed publisher
    ..and using chromatin immunoprecipitation and western blotting, we identify the transcription factor EBF1 (early B-cell factor 1) as an interaction partner for TET2, suggesting a sequence-specific mechanism for regulating DNA methylation.
  57. de la Rica L, Rodriguez Ubreva J, García M, Islam A, Urquiza J, Hernando H, et al. PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol. 2013;14:R99 pubmed
    ..Moreover, PU.1 interacts with both DNMT3b and TET2, suggesting its participation in driving hypermethylation and hydroxymethylation-mediated hypomethylation...
  58. Solary E, Bernard O, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28:485-96 pubmed publisher
    Ten-Eleven Translocation-2 (TET2) inactivation through loss-of-function mutation, deletion and IDH1/2 (Isocitrate Dehydrogenase 1 and 2) gene mutation is a common event in myeloid and lymphoid malignancies...
  59. Couronné L, Bastard C, Bernard O. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366:95-6 pubmed publisher
  60. Garcia Gomez A, Li T, Kerick M, Català Moll F, Comet N, Rodriguez Ubreva J, et al. TET2- and TDG-mediated changes are required for the acquisition of distinct histone modifications in divergent terminal differentiation of myeloid cells. Nucleic Acids Res. 2017;45:10002-10017 pubmed publisher
    ..b>TET2, a methylcytosine dioxygenase highly expressed in these cells and frequently mutated in myeloid leukemias, may be a ..
  61. Makishima H. Sequential acquisition of mutations in myelodysplastic syndromes. Rinsho Ketsueki. 2017;58:1828-1837 pubmed publisher
    ..In blood samples from healthy elderly individuals, somatic DNMT3A and TET2 mutations are detected as age-related clonal hematopoiesis and are believed to be a risk factor for hematological ..
  62. Yamazaki J, Taby R, Jelinek J, Raynal N, Cesaroni M, Pierce S, et al. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. J Natl Cancer Inst. 2015;108: pubmed publisher
    Acute myeloid leukemia (AML) is curable in a subset of cases. The DNA methylation regulator TET2 is frequently mutated in AML, and we hypothesized that studying TET2-specific differentially methylated CpGs (tet2-DMCs) improves AML ..
  63. Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, et al. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. Leuk Res. 2017;65:1-4 pubmed publisher
    ..Twenty patients of each group were screened with regard to ASXL1, TET2, RUNX1, SETBP1, NRAS, and SRSF2 using Illumina myeloid panel...
  64. Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2013;27:1044-52 pubmed publisher
    ..1%) and 2 of 5 CCAAT/enhancer-binding protein-? (40%) mutations. However, epigenetics-modifying gene (DNMT3a, TET2 and IDH1/2) mutations had no change between diagnosis and relapse samples, and may become minimal residual disease ..
  65. Schönberger K, Cabezas Wallscheid N. Vitamin C: C-ing a New Way to Fight Leukemia. Cell Stem Cell. 2017;21:561-563 pubmed publisher
    ..Two new studies in Nature and Cell, from Agathocleous et al. (2017) and Cimmino et al. (2017), respectively, show that vitamin C regulates HSC function and suppresses leukemogenesis by modulating Tet2 activity.
  66. Alayed K, Patel K, Konoplev S, Singh R, Routbort M, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055-61 pubmed publisher
    ..Targeted next-generation sequencing performed on five BPDCN cases identified TET2 (ten eleven translocation 2) mutations and no other AML-associated mutations...
  67. Euba B, Vizmanos J, García Granero M, Aranaz P, Hurtado C, Miguéliz I, et al. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. Leuk Lymphoma. 2012;53:1230-3 pubmed publisher
  68. Wei J, Chen G, Qiu H, Fu C, Ding Z, Liu H, et al. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients]. Zhonghua Xue Ye Xue Za Zhi. 2011;32:304-7 pubmed
    To evaluate the prevalence of TET2 gene mutation in acute myeloid leukemia (AML) patients, and analyze their clinical characteristics and prognosis...